Company Filing History:
1 out of 512 
1 out of 8 Years Active: 2025
Title: The Innovative Contributions of Daniel Alan Heller
Introduction
Daniel Alan Heller is a prominent inventor based in New York, NY, known for his significant contributions to cancer therapy through innovative drug delivery systems. His work focuses on the development of PI3K inhibitors, which play a crucial role in treating various proliferative diseases, including cancer. With a patent portfolio that includes one notable patent, Heller's research has the potential to transform cancer treatment paradigms.
Latest Patents
Heller's patent, titled "PI3K inhibitors and uses thereof," represents a significant advancement in targeted drug delivery. This patent outlines the development of improved PI3K inhibitors, specifically PI3Kα inhibitors, which are essential for effective cancer therapy. The patent details various compounds, including pharmaceutically acceptable salts, hydrates, and nanoparticles designed for targeted delivery to cancer cells. These innovations aim to enhance the efficacy of cancer treatments and improve patient outcomes.
Career Highlights
Throughout his career, Daniel Alan Heller has worked with esteemed institutions such as the Sloan-Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. His research has focused on creating novel therapeutic strategies that leverage the capabilities of PI3K inhibitors. Heller's work has garnered attention for its potential to significantly impact cancer treatment methodologies.
Collaborations
Heller has collaborated with notable colleagues in the field, including Makoto Fushimi and Maurizio Scaltriti. These partnerships have facilitated the advancement of research and development in cancer therapies, contributing to the collective knowledge and innovation in the medical community.
Conclusion
Daniel Alan Heller's contributions to the field of cancer therapy through his innovative work on PI3K inhibitors highlight the importance of targeted drug delivery systems. His research and patent represent a promising step forward in the fight against cancer, showcasing the potential for improved treatment options.